Related Experiment Video
Updated: Oct 2, 2025
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.6K
IDH1/2 mutations in acute myeloid leukemia
Ja Min Byun1,2, Seung-Joo Yoo1,2, Hyeong-Joon Kim3
1Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
Blood Research
|February 24, 2022
Summary
Mutations in isocitrate dehydrogenase (IDH) genes are key in acute myeloid leukemia (AML). This review examines IDH1/2 mutations in Korean AML patients, highlighting their role as biomarkers and therapeutic targets.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Acute myeloid leukemia (AML) research has advanced understanding of its mutational and epigenetic landscape.
- Isocitrate dehydrogenase (IDH) genes are recognized as critical mutational hotspots in AML.
- Precision medicine strategies are increasingly informed by these biological insights.
Purpose of the Study:
- To review the IDH1/2 mutation landscape specifically within the Korean AML patient population.
- To compare these findings with existing global public data on IDH1/2 mutations in AML.
- To discuss the significance of IDH1/2 mutations as predictive biomarkers and therapeutic targets in AML.
Main Methods:
- Literature review and data synthesis.
- Analysis of mutation data from Korean AML patients.
- Comparison with publicly available datasets.
Main Results:
- Overview of the IDH1/2 mutation landscape in Korean AML patients.
- Comparative analysis with international AML mutation data.
- Identification of IDH1/2 mutations' roles in AML pathogenesis and treatment.
Conclusions:
- IDH1/2 mutations are increasingly recognized as crucial factors in AML treatment.
- Thorough examination and monitoring of IDH1/2 mutations are essential throughout the clinical management of AML.
- Understanding the IDH1/2 mutation landscape supports the development of targeted therapies for AML.
